Relmada Therapeutics (RLMD) Receivables (2022)
Relmada Therapeutics (RLMD) reported Receivables of $1.0 million for Q4 2022.
Relmada Therapeutics (RLMD) has 1 years of Receivables data on file, last reported at $1.0 million in Q4 2022.
- Quarterly Receivables changed N/A year-over-year to $1.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.0 million (changed N/A YoY) and the FY2022 annual result came in at $1.0 million, changed N/A from the prior year.
- Receivables was little changed at $1.0 million in Q4 2022 per RLMD's latest filing.
- Across five years, Receivables topped out at $1.0 million in Q4 2022 and bottomed at $1.0 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.02 Mn |